Dongxing Zha

Company: Alloy Therapeutics

Job title: CTO - TCR Discovery & Engineering , Alloy Therapeutics Founder & CEO, Keyway TCR Discovery

Seminars:

KeywayTM TCRm T-cell Engagers Discovery and Engineering: Fully Integrated Workflow from Target Idea to Development Candidate 12:30 pm

TCRm antibody enable the targeting of intracellular proteins that have not been addressed by conventional cancer immunotherapies while avoiding the manufacturing and regulatory challenges of other TCR-based modalities Keyway TCRm Discovery is the industry leading service to deliver fully functional and highly-specific lead TCRm T cell engagers by integrating high quality pMHC generation, best-in-class antibody…Read more

day: Conference Day 1